Skip to search formSkip to main contentSkip to account menu

PI3K-delta Inhibitor TGR-1202

Known as: TGR-1202 
An orally bioavailable, selective inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinases (PI3K) with… 
National Institutes of Health

Related topics

Related topics

2 relations
NCIt Antineoplastic Agent Terminology

Narrower (1)

RP5264

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
An Integrated Safety Analysis of the Next Generation PI3Kδ Inhibitor Umbralisib (TGR-1202) in Patients with Relapsed/Refractory Lymphoid Malignancies
Matthew S. Davids, MD1, Ian W. Flinn, MD, PhD2,3, Anthony R. Mato, MD4, Owen A. O'Connor, M.D., Ph.D.5, Danielle M. Brander, MD6… 
2017
2017
UPDATED RESULTS OF A MULTICENTER PHASE I/IB STUDY OF TGR‐1202 IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY MCL OR CLL
2016
2016
Long-term follow-up of the PI3K{delta} inhibitor TGR-1202 to demonstrate a differentiated safety profile and high response rates in CLL and NHL: Integrated-analysis of TGR-1202 monotherapy and…
7512Background: TGR-1202 is a novel, once-daily PI3Kδ inhibitor with a differentiated safety profile from other PI3Kδ inhibitors… 
2016
2016
TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL: Preliminary Results of a Multicenter Phase I/Ib Study
Introduction The oral BTK inhibitor ibrutinib is highly effective at inducing partial responses (PR) in relapsed or refractory (R… 
2015
2015
TGR-1202, a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile in Patients with CLL and B-Cell Lymphoma
Background: TGR-1202 is a novel, next generation PI3Kδ inhibitor which exhibits a differentiated safety profile from other PI3K… 
2015
2015
A Phase I Trial of TGR-1202, a Next Generation Once Daily PI3K-Delta Inhibitor in Combination with Obinutuzumab Plus Chlorambucil, in Patients with Chronic Lymphocytic Leukemia
Introduction: TGR-1202 is a next generation, once daily, oral PI3Kδ inhibitor that displays promising clinical activity in… 
2015
2015
Ublituximab + TGR-1202 Demonstrates Activity and a Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL: Phase I Results
Introduction: Ublituximab (UTX) is a novel anti-CD20 mAb that has been glycoengineered for enhanced ADCC. TGR-1202 is a novel… 
2014
2014
Activity of TGR-1202, a novel once-daily PI3K{delta} inhibitor, in patients with relapsed or refractory hematologic malignancies.
2513 Background: TGR-1202 is a novel, next generation PI3Kδ inhibitor. Preliminary data from an ongoing Ph I study of TGR-1202… 
2014
2014
TGR-1202, a Novel Once Daily PI3Kδ Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity, in Patients with Chronic Lymphocytic Leukemia and B-Cell Lymphoma
Background: TGR-1202 is a novel oral, next generation PI3Kδ inhibitor which notably lacks the hepatotoxicity associated with… 
2013
2013
The PI3K Delta Inhibitor TGR-1202 and Proteasome Inhibitor Carfilzomib Are Highly Synergistic In Killing Human B- and T-Cell Lymphoma Cells
Background The constitutively activated PI3K/AKT/mTOR pathway plays a key role in the proliferation and survival of cancer cells… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)